ATAI Investor Day Presentation Deck
atai executive summary & key highlights
atai
LIFE SCIENCES
4
5
6
сл
Mental health disorders have become one of largest global health burdens. Despite the
unmet patient need, innovations remain limited.
As a response to the technical risks associated with CNS drug development, atai focuses
on compounds with prior evidence in humans.
Our platform consists of 11 drug development programs and 6 enabling technologies,
focusing on differentiated, potentially disease-modifying therapies.
We employ a decentralized drug development process, leveraging the atai team and our
enabling technologies to aim for improved safety, efficacy and probability of clinical
success across our pipeline.
Validation of atai's operating model: IPO of COMPASS Pathways and Otsuka partnership
with Perception.
We have a team of more than 200 highly experienced FTES/ consultants across our
platform, and a strong cash position of approx. $430M.
14View entire presentation